These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 15340386)

  • 1. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics: bench to bedside.
    Weinshilboum R; Wang L
    Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Apr; 73(68):19074-6. PubMed ID: 18677821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 9. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics: role in medicines approval and clinical use.
    Novelli G; Borgiani P; Ciccacci C; Di Daniele N; Sirugo G; Papaluca Amati M
    Public Health Genomics; 2010; 13(5):284-91. PubMed ID: 19815999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
    Goodsaid F; Frueh FW
    Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics and its implications for autoimmune disease.
    Ross CJ; Katzov H; Carleton B; Hayden MR
    J Autoimmun; 2007; 28(2-3):122-8. PubMed ID: 17418528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should pharmacogenomic studies be required for new drug approval?
    Relling MV; Hoffman JM
    Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 19. The ethical implications of stratifying by race in pharmacogenomics.
    Lee SS
    Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics: will the regulators approve?
    Hodgson J; Marshall A
    Nat Biotechnol; 1998 Mar; 16(3):243-6. PubMed ID: 9528002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.